Intravenous Glutathione Does Not Cause Kidney Injury
Based on available evidence, intravenous glutathione infusion does not cause kidney injury and may actually provide nephroprotection in certain clinical contexts.
Evidence from FDA-Approved Products
The FDA-approved glutathione-containing product BSS PLUS® (used for intraocular irrigation during ophthalmic surgery) explicitly states it is "NOT FOR INJECTION OR INTRAVENOUS INFUSION" 1. However, this warning pertains specifically to this ophthalmic irrigation solution formulation and its intended use, not to properly formulated intravenous glutathione preparations used systemically.
Research Evidence Supporting Safety and Nephroprotection
Protective Effects in Acute Kidney Injury
Multiple studies demonstrate that intravenous glutathione actually protects against kidney injury rather than causing it:
In STEMI patients undergoing primary PCI: Intravenous glutathione sodium salt (GSS) infusion significantly reduced contrast-associated acute kidney injury (CA-AKI) occurrence. CA-AKI developed in only 10% of patients receiving GSS versus 38% in the placebo group (p < 0.001). GSS administration was an independent predictor of CA-AKI prevention (OR 0.17,95% CI 0.04-0.61) 2.
In coronary angiography patients: Intravenous glutathione (100 mg/min for 30 minutes before procedure) completely abolished the increase in urinary lipid hydroperoxides and prevented the decrease in serum GSH levels that occurred in control patients, demonstrating effective prevention of contrast medium-induced renal oxidative stress 3.
In animal models of ischemic AKI: Intravenous GSH administration (2 mmol/kg every 3 hours) resulted in significant amelioration of glycerol-induced acute renal failure, with blood urea nitrogen of 78 ± 10 mg/dL versus 96 ± 10 mg/dL in untreated animals (p < 0.05) 4.
Pharmacokinetics and Safety Profile
A study in healthy volunteers receiving high-dose intravenous glutathione (2 g/m²) demonstrated:
- Rapid elimination with a half-life of 14.1 ± 9.2 minutes
- Increased plasma cysteine availability (from 8.9 to 114 μmol/L)
- Enhanced intracellular cysteine uptake
- No adverse renal effects reported 5
Mechanism of Nephroprotection
Glutathione protects kidneys through multiple mechanisms:
- Direct antioxidant effects: Scavenges reactive oxygen species more effectively than oral N-acetylcysteine 3
- Maintains cellular GSH levels: Prevents depletion that occurs during oxidative stress 4
- Supports mitochondrial function: Provides substrate for cellular energy production 6
- Inhibits ferroptosis: A key pathway in AKI pathogenesis 7
Clinical Context and Caveats
Important distinction: The evidence provided about gadolinium-based contrast media (GBCM) and nephrogenic systemic fibrosis [8-8] is not relevant to glutathione administration. These guidelines address an entirely different substance (gadolinium contrast agents) and different toxicity mechanism.
Key point: Glutathione depletion (not administration) worsens kidney injury. Studies using glutathione synthesis inhibitors like buthionine sulfoximine demonstrate significantly worse renal failure when endogenous glutathione is depleted 4.
Dosing considerations: The protective effects are dose-dependent and timing-dependent. Pre-treatment before nephrotoxic insults (contrast media, ischemia) appears most effective 2, 3.